Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,700,046
  • Shares Outstanding, K 280,945
  • Annual Sales, $ 305,510 K
  • Annual Income, $ -250,460 K
  • 60-Month Beta 0.88
  • Price/Sales 11.75
  • Price/Cash Flow N/A
  • Price/Book 28.02
Trade FOLD with:

Options Overview Details

View History
  • Implied Volatility 53.75% ( +9.54%)
  • Historical Volatility 40.79%
  • IV Percentile 8%
  • IV Rank 14.09%
  • IV High 140.85% on 10/14/22
  • IV Low 39.47% on 03/04/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 264
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 6,396
  • Open Int (30-Day) 15,267

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.13
  • Number of Estimates 4
  • High Estimate -0.04
  • Low Estimate -0.22
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +55.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.14 +15.17%
on 01/10/23
13.61 -5.77%
on 01/18/23
+1.30 (+11.27%)
since 12/27/22
3-Month
9.10 +40.99%
on 11/07/22
13.61 -5.77%
on 01/18/23
+2.45 (+23.60%)
since 10/27/22
52-Week
5.91 +117.09%
on 05/09/22
13.61 -5.77%
on 01/18/23
+4.13 (+47.47%)
since 01/27/22

Most Recent Stories

More News
Why Is Amicus Therapeutics (FOLD) Up 13.7% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FOLD : 12.83 (-2.58%)
HZNP : 110.63 (-0.56%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such...

FOLD : 12.83 (-2.58%)
Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

AVEO : 15.00 (unch)
FOLD : 12.83 (-2.58%)
PBYI : 4.24 (-4.07%)
KOD : 7.88 (-0.38%)
Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 36.84% and 3.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 12.83 (-2.58%)
PULM : 4.07 (+2.01%)
Amicus Therapeutics: Q3 Earnings Snapshot

Amicus Therapeutics: Q3 Earnings Snapshot

FOLD : 12.83 (-2.58%)
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AGLE : 0.5100 (+3.45%)
FOLD : 12.83 (-2.58%)
TuSimple, Howmet fall; XPO Logistics, Wynn Resorts rise

Stocks that traded heavily or had substantial price changes Monday: TuSimple, Howmet fall; XPO Logistics, Wynn Resorts rise

FOLD : 12.83 (-2.58%)
ALGN : 269.20 (+2.38%)
VRSK : 180.15 (-0.46%)
CS : 3.56 (-0.28%)
XPO : 39.39 (+3.96%)
WYNN : 102.99 (+0.14%)
Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

FOLD : 12.83 (-2.58%)
SRRK : 12.66 (+1.12%)
BNTX : 143.66 (+0.79%)
PLRX : 34.87 (-3.83%)
Amicus Therapeutics (FOLD) Reports Q2 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 8.70% and 5.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 12.83 (-2.58%)
CCCC : 7.84 (+2.35%)
Amicus Therapeutics Announces Second Quarter 2022 Financial Results

1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7% On-Track to...

FOLD : 12.83 (-2.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is...

See More

Key Turning Points

3rd Resistance Point 13.52
2nd Resistance Point 13.36
1st Resistance Point 13.10
Last Price 12.83
1st Support Level 12.68
2nd Support Level 12.52
3rd Support Level 12.26

See More

52-Week High 13.61
Last Price 12.83
Fibonacci 61.8% 10.67
Fibonacci 50% 9.76
Fibonacci 38.2% 8.85
52-Week Low 5.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar